Document is current
Any future updates will be listed below
-
Authors
Buxbaum Grice, Ariela S.
Sloofman, Laura
Levy, Tess
Walker, Hannah
Ganesh, Gauri
Rodriguez de los Santos, Miguel
Amini, Pardis
Buxbaum, Joseph D. https://orcid.org/0000-0001-8898-8313
Kolevzon, Alexander
Kostic, Ana
Breen, Michael S. https://orcid.org/0000-0002-6739-939X
- License Information
-
More Information
Article History
Received: 2 August 2023
Revised: 26 June 2024
Accepted: 2 July 2024
First Online: 25 July 2024
Competing interests
: Alexander Kolevzon is on the scientific advisory boards of Ovid Therapeutics, Ritrova Therapeutics, and Jaguar Therapeutics and consults to Acadia, Alkermes, GW Pharmaceuticals, Neuren Pharmaceuticals, Clinilabs Drug Development Corporation, and Scioto Biosciences. Joseph D. Buxbaum consults for BridgeBio Pharma. The remainder of the authors declare no competing interests.
: All study participants have given written informed consent.
: The genetic study has been approved by the Icahn School of Medicine at Mount Sinai Institutional Review Board.
